Supernus Pharmaceuticals (SUPN) Projected to Post Earnings on Thursday

Supernus Pharmaceuticals (NASDAQ:SUPN) will likely be releasing its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect Supernus Pharmaceuticals to post earnings of $0.49 per share and revenue of $217.56 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%. The business had revenue of $219.06 million during the quarter, compared to analyst estimates of $205.31 million. During the same quarter in the previous year, the company earned $0.40 EPS. The firm’s revenue was up 32.4% compared to the same quarter last year. On average, analysts expect Supernus Pharmaceuticals to post $1.79 EPS for the current fiscal year and $3.68 EPS for the next fiscal year.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock opened at $40.77 on Tuesday. The stock has a market cap of $2.37 billion, a PE ratio of -21.23, a price-to-earnings-growth ratio of 1.20 and a beta of 0.55. The firm has a fifty day moving average price of $43.05 and a 200 day moving average price of $47.52. Supernus Pharmaceuticals has a 1 year low of $37.54 and a 1 year high of $59.68.

Analyst Ratings Changes

Several brokerages have weighed in on SUPN. Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Cantor Fitzgerald upped their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, September 21st. Finally, Wall Street Zen lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Supernus Pharmaceuticals currently has an average rating of “Hold” and an average target price of $63.00.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.